Suppr超能文献

60岁及以上成年人的全国及各州带状疱疹疫苗接种情况

National and State-Specific Shingles Vaccination Among Adults Aged ≥60 Years.

作者信息

Lu Peng-Jun, O'Halloran Alissa, Williams Walter W, Harpaz Rafael

机构信息

Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

出版信息

Am J Prev Med. 2017 Mar;52(3):362-372. doi: 10.1016/j.amepre.2016.08.031. Epub 2016 Oct 5.

Abstract

INTRODUCTION

Shingles (herpes zoster) causes substantial morbidity, especially among older adults. The shingles vaccine has been recommended for people aged ≥60 years since 2006. This study assessed recent shingles vaccination at national and state levels among adults aged ≥60 years.

METHODS

The 2014 Behavioral Risk Factor Surveillance System data were analyzed in 2015 to assess shingles vaccination coverage among adults aged ≥60 years at national and state levels. Multivariable logistic regression and predictive marginal models identified factors independently associated with vaccination.

RESULTS

Shingles vaccination coverage among adults aged ≥60 years was 31.8% (95% CI=31.4%, 32.2%). Among states, shingles vaccination coverage ranged from 17.8% (95% CI=15.8%, 20.0%) in Mississippi to 46.6% (95% CI=44.3%, 48.8%) in Vermont, with a median of 33.3%. Coverage was <25% in four states and >40% in nine states. For all states, coverage was significantly higher among non-Hispanic whites compared with non-white races except for Oregon, with coverage differences ranging from -33.2% in the District of Columbia to 0.9% in Oregon and a median of -16.0%. Characteristics independently associated with vaccination were age, race/ethnicity, sex, education, employment status, household income, region, perceived health status, health insurance status, personal healthcare provider, routine checkup status, and whether reporting that cost was a barrier to seeing a doctor.

CONCLUSIONS

Coverage varied dramatically by state. State-level comparisons may aid in designing tailored intervention programs through sharing of best practices. Strategies are needed to mitigate financial barriers for both provider and patients, improve awareness, and increase provider recommendation of the vaccine.

摘要

引言

带状疱疹会引发严重疾病,尤其是在老年人中。自2006年起,带状疱疹疫苗就被推荐给60岁及以上的人群。本研究评估了60岁及以上成年人在国家和州层面的近期带状疱疹疫苗接种情况。

方法

2015年对2014年行为危险因素监测系统的数据进行了分析,以评估国家和州层面60岁及以上成年人的带状疱疹疫苗接种覆盖率。多变量逻辑回归和预测边际模型确定了与疫苗接种独立相关的因素。

结果

60岁及以上成年人的带状疱疹疫苗接种覆盖率为31.8%(95%置信区间=31.4%,32.2%)。在各州中,带状疱疹疫苗接种覆盖率从密西西比州的17.8%(95%置信区间=15.8%,20.0%)到佛蒙特州的48.8%(95%置信区间=44.3%,48.8%)不等,中位数为33.3%。四个州的覆盖率低于25%,九个州的覆盖率高于40%。对于所有州,除俄勒冈州外,非西班牙裔白人的覆盖率显著高于非白人种族,覆盖率差异从哥伦比亚特区的-33.2%到俄勒冈州的0.9%不等,中位数为-16.0%。与疫苗接种独立相关的特征包括年龄、种族/族裔、性别、教育程度、就业状况、家庭收入、地区、自我感知的健康状况、健康保险状况、个人医疗服务提供者、定期体检状况,以及是否报告费用是看医生的障碍。

结论

各州的覆盖率差异很大。州层面的比较可能有助于通过分享最佳实践来设计量身定制的干预项目。需要采取策略来减轻提供者和患者的经济障碍,提高认识,并增加提供者对该疫苗的推荐。

相似文献

1
National and State-Specific Shingles Vaccination Among Adults Aged ≥60 Years.
Am J Prev Med. 2017 Mar;52(3):362-372. doi: 10.1016/j.amepre.2016.08.031. Epub 2016 Oct 5.
2
Herpes zoster vaccination: Primary care provider knowledge, attitudes, and practices.
Hum Vaccin Immunother. 2025 Dec;21(1):2488093. doi: 10.1080/21645515.2025.2488093. Epub 2025 Apr 18.
3
Shingles vaccination uptake in Massachusetts adults aged 50 years and older.
Vaccine. 2021 Nov 5;39(46):6781-6786. doi: 10.1016/j.vaccine.2021.09.032. Epub 2021 Oct 5.
4
Shingles Vaccination of U.S. Adults Aged 50-59 Years and ≥60 Years Before Recommendations for Use of Recombinant Zoster Vaccine.
Am J Prev Med. 2020 Jul;59(1):21-31. doi: 10.1016/j.amepre.2020.01.017. Epub 2020 May 7.
5
Noninfluenza vaccination coverage among adults - United States, 2012.
MMWR Morb Mortal Wkly Rep. 2014 Feb 7;63(5):95-102.
6
Assessing and Improving Zoster Vaccine Uptake in a Homeless Population.
J Community Health. 2018 Dec;43(6):1019-1027. doi: 10.1007/s10900-018-0517-x.
7
Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2348839. doi: 10.1080/21645515.2024.2348839. Epub 2024 May 28.
10

引用本文的文献

1
The association between healthcare access and shingles vaccination among older adults in Virginia, United States.
PLoS One. 2025 Apr 15;20(4):e0316429. doi: 10.1371/journal.pone.0316429. eCollection 2025.
2
Respiratory syncytial virus vaccination among US adults aged ≥60 years.
Front Immunol. 2024 Dec 3;15:1427550. doi: 10.3389/fimmu.2024.1427550. eCollection 2024.
4
Shingles Vaccine Uptake Among Older Adults: Identifying Early, Later, and Nonadopters.
AJPM Focus. 2023 Sep 21;2(4):100143. doi: 10.1016/j.focus.2023.100143. eCollection 2023 Dec.
5
Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data.
Vaccine. 2023 May 26;41(23):3493-3496. doi: 10.1016/j.vaccine.2023.04.067. Epub 2023 May 6.
6
Consumer Perceptions of a Shingles Infograph Intervention and Vaccination Plans in Community Pharmacy Settings.
Innov Pharm. 2022 Dec 12;13(3). doi: 10.24926/iip.v13i3.4918. eCollection 2022.
9
Vaccination Coverage of the Elderly in Greece: A Cross-Sectional Nationwide Study.
Can J Infect Dis Med Microbiol. 2020 Jun 27;2020:5459793. doi: 10.1155/2020/5459793. eCollection 2020.
10
Incidence Rate of Herpes Zoster Ophthalmicus: A Retrospective Cohort Study from 1994 through 2018.
Ophthalmology. 2020 Mar;127(3):324-330. doi: 10.1016/j.ophtha.2019.10.001. Epub 2019 Oct 9.

本文引用的文献

1
Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014.
MMWR Surveill Summ. 2016 Feb 5;65(1):1-36. doi: 10.15585/mmwr.ss6501a1.
2
Racial and Ethnic Disparities in Vaccination Coverage Among Adult Populations in the U.S.
Am J Prev Med. 2015 Dec;49(6 Suppl 4):S412-25. doi: 10.1016/j.amepre.2015.03.005. Epub 2015 Aug 18.
3
Impact of health insurance status on vaccination coverage among adult populations.
Am J Prev Med. 2015 Jun;48(6):647-61. doi: 10.1016/j.amepre.2014.12.008. Epub 2015 Apr 15.
4
Update on recommendations for use of herpes zoster vaccine.
MMWR Morb Mortal Wkly Rep. 2014 Aug 22;63(33):729-31.
5
Systematic review of incidence and complications of herpes zoster: towards a global perspective.
BMJ Open. 2014 Jun 10;4(6):e004833. doi: 10.1136/bmjopen-2014-004833.
6
Recommendations from the National Vaccine Advisory committee: standards for adult immunization practice.
Public Health Rep. 2014 Mar-Apr;129(2):115-23. doi: 10.1177/003335491412900203.
7
Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.
Vaccine. 2014 Mar 26;32(15):1645-53. doi: 10.1016/j.vaccine.2014.01.058. Epub 2014 Feb 15.
8
Incidence of herpes zoster in patients with altered immune function.
Infection. 2014 Apr;42(2):325-34. doi: 10.1007/s15010-013-0550-8. Epub 2013 Nov 10.
10
Improving herpes zoster vaccination rates through use of a clinical pharmacist and a personal health record.
Am J Med. 2013 Sep;126(9):832.e1-6. doi: 10.1016/j.amjmed.2013.02.018. Epub 2013 Jul 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验